Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuebijing injection for severe COVID-19 in ICU patients
ChiCTR2000029381Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2020
- Countries
- 1
01
Overview
Phase 4, open-label trial of xuebijing in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Pneumonia severity index. Started Jan 2020; status: completed.
02
Drugs
xuebijing
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000029381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029381.